The different reduction rate of prostate-specific antigen in dutasteride and finasteride

Korean Journal of Urology

Volumn 51, Issue 10, 2010, Pages 704-708

  Choi, Yong Hyeuk ^a   Cho, Sung Yong ^a   Cho, In Rae ^a  

^a Inje University   (South Korea)

Author keywords

Dutasteride; Finasteride; Prostate specific antigen; Prostatic hyperplasia

Indexed keywords

ALFUZOSIN; DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; PROSTATE HYPERTROPHY; TRANSRECTAL ULTRASONOGRAPHY; URINE VOLUME;

EID: 78149340943     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2010.51.10.704     Document Type: Article

References (28)

1. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003;361:1359-67.
2. Holtgrewe HL, Mebust WK, Dowd JB, Cockett AT, Peters PC, Proctor C. Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol 1989;141:248-53.
3. Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms - a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995;54:273-9.
4. Titus MA, Gregory CW, Ford OH 3rd, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365-71.
5. Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol 2005;7:203-10.
6. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Finasteride Study Group. Prostate 1993;22:291-9.
7. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488-94.
8. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505-8.
9. Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, et al. Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 1999;161:332-7.
10. Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004;172:915-9.
11. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557-63.
12. Fenter TC, Davis EA, Shah MB, Lin PJ. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. Am J Manag Care 2008;14(5 Suppl 2):S154-9.
13. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther 2007;29:17-25. (Pubitemid 46414037)
14. Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005;96:572-7.
15. O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003;92:262-6.
16. Issa MM, Runken MC, Grogg AL, Shah MB. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. Am J Manag Care 2007;13(Suppl 1):S10-6.
17. Milam D, Oesterling JE, Roehrborn CG, Auerbach S, Padley RJ. Serial prostate-specific antigen measurements in patients with clinical benign prostatic hyperplasia enrolled in a randomized, double-blinded, placebo-controlled study with terazosin. J Urol 1995;153(Suppl):396A
18. Brown JA, Peterson DD, Lieber MK, Oesterling JE. Terazosin and finasteride both lower the serum prostate-specific antigen (PSA) level in men with benign prostatic hyperplasia (BPH). J Urol 1996;155(Suppl):424A
19. Bozeman CB, Carver BS, Eastham JA, Venable DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol 2002;167:1723-6.
20. Potts JM. Prospective identification of National Institutes of Health category Category IV prostatitis in men with elevated prostate specific antigen. J Urol 2000;164:1550-3.
21. Fowke JH, Motley SS, Smith JA Jr, Cookson MS, Concepcion R, Chang SS, et al. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J Urol 2009;181:2064-70.
22. Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol Clin North Am 1993;20:627-36.
23. Espana F, Martinez M, Royo M, Estelles A, Alapont JM, Navarro S, et al. Changes in molecular forms of prostate-specific antigen during treatment with finasteride. BJU Int 2002;90:672-7.
24. Hong JE, Hong SJ. Changes in prostate volume, transitional zone volume and PSA after cessation of the finasteride. Korean J Urol 1999;40:1519-24.
25. Brawer MK, Lin DW, Williford WO, Jones K, Lepor H. Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. Prostate 1999;39:234-9.
26. Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998;52:195-201.
27. Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol 2006;175:1657-62.
28. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.